Research Highlights

 
Stock Quotes for Research Highlights top ^
  • Industry: Apparel Manufacturing
  • Sector: Consumer Cyclical
  • Stock Style: Small Core
Sign-up for 01682 investment picks
  • Industry: Lodging
  • Sector: Consumer Cyclical
  • Stock Style: Small Core
Sign-up for l60 investment picks
  • Industry: Media - Diversified
  • Sector: Consumer Cyclical
  • Stock Style: Small Core
Sign-up for hlg investment picks

 
News Articles for Research Highlights top ^
3 rd Quarter Highlights : EVANSVILLE, Ind., Oct.
Sign-up for Old National's 3rd Quarter Highlighted by 6.5% Annualized Organic Loan Growth (Excluding Covered Loans) and a Continued Strong Loan Pipeline investment picks
http://media.marketwire.com/attachments/201402/71846_hansenlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1157121&ProfileId=051205&sourceType=1 MOUNTAIN VIEW, CA --
Sign-up for Hansen Medical Reports Third Quarter 2014 Operating Results and Recent Business Highlights investment picks
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
Sign-up for Heron Therapeutics Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the third quarter ended September 30, 2014.
Sign-up for Ignyta Announces Third Quarter 2014 Company Highlights and Financial Results investment picks
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress and near-term milestones.
Sign-up for La Jolla Pharmaceutical Company Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights investment picks
- Demonstrated Human Proof-of-Concept; 'Clinical Map Initiative' Updated - - Strengthened Financial Position with Public Offering of Common Stock; Guidance Updated to End 2014 with Greater Than $150 Million in Cash - LA JOLLA, Calif.
Sign-up for Regulus Reports Third Quarter 2014 Financial Results and Recent Highlights investment picks
NeuroMetrix, Inc. (the “Company”) (Nasdaq: NURO), today reported business highlights for the quarter ended September 30, 2014.
Sign-up for NeuroMetrix Reports Third Quarter 2014 Financial Results and Business Highlights investment picks
XenoPort (NASDAQ:XNPT) today reported an update on prescription trends and further development of HORIZANT ® (gabapentin enacarbil) Extended-Release Tablets, including feedback from the U.S. Food and Drug Administration (FDA) on development for treatment of alcohol use disorder (AUD). HORIZANT prescription trend highlights include: The number of nation-wide prescribed tablets for the 13 weeks ending December 19, 2014 was 1,256,082, an increase of 18% compared to the prior 13 weeks ending September 19, 2014 and an increase of 95% over the 13-week period ending December 20, 2013.* The rolling four-week average of prescribed tablets for the week ending December 19, 2014 was 100,742.* The current wholesale acquisition cost (WAC) price is $7.69 per tablet.
Sign-up for XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder investment picks
GLASTONBURY, Conn., Oct.
Sign-up for United Financial Bancorp, Inc. Third Quarter Performance Highlighted by Strong Organic Growth investment picks
Pershing Gold CEO Stephen Alfers Presents at Noble Financial Capital Markets Conference and Highlights Landmark Deal Canada NewsWire LAKEWOOD, Colo.
Sign-up for Pershing Gold CEO Stephen Alfers Presents at Noble Financial Capital Markets Conference and Highlights Landmark Deal investment picks
2015/1/16
Freegold Provides Update and Highlights Important 2014 Milestones Canada NewsWire VANCOUVER , Jan.
Sign-up for Freegold Provides Update and Highlights Important 2014 Milestones investment picks
Alnylam Pharmaceuticals, Inc .
Sign-up for Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results and Highlights Recent Period Progress investment picks
LEXINGTON, Mass., Nov.
Sign-up for T2 Biosystems Reports 2014 Third Quarter Highlights and Financial Results investment picks
Ignyta, Inc. (Nasdaq: RXDX), an precision oncology biotechnology company, announced today that it will release its third quarter 2014 financial results after the market closes on Friday, November 7, 2014.
Sign-up for Ignyta to Report 2014 Third Quarter Company Highlights and Financial Results and Host Conference Call on November 7, 2014 investment picks
http://media.marketwire.com/attachments/200909/562613_checkpointlogo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1154287&ProfileId=051205&sourceType=1 SAN CARLOS, CA --
Sign-up for Check Point's Third Annual Mobile Security Survey Highlights Careless Employees as Greatest Mobile Security Threat investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Highlights
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Guides  |  Next: Research Hospital